A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer

被引：47

作者：

Wu, Xiujuan ^{[1
]}

Tang, Peng ^{[1
]}

Li, Shifei ^{[1
]}

Wang, Shushu ^{[1
]}

Liang, Yueyang ^{[1
]}

Zhong, Ling ^{[1
]}

Ren, Lin ^{[1
]}

Zhang, Ting ^{[1
]}

Zhang, Yi ^{[1
]}

机构：

[1] Third Mil Med Univ, Southwest Hosp, Breast Dis Ctr, Chongqing 400038, Peoples R China

来源：

NATURE COMMUNICATIONS | 2018年 / 9卷

关键词：

PATHOLOGICAL COMPLETE RESPONSE; ARTERIAL CHEMOEMBOLIZATION; ANTITUMOR-ACTIVITY; CHEMOTHERAPY; DOCETAXEL; CARBOPLATIN; EPIRUBICIN; PACLITAXEL; CISPLATIN; DOXORUBICIN;

D O I：

10.1038/s41467-018-03210-2

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Currently, one sixth of triple-negative breast cancer (TNBC) patients who receive docetaxel (T) and epirubicin (E) as neoadjuvant chemotherapy achieve a pathologic complete response (pCR). This study evaluates the impact of adding lobaplatin (L) to the TE regimen. Here, we show data from 125 patients (63 TE and 62 TEL patients). Four patients did not complete all the cycles. Two-sided P values show that the addition of L (38.7% vs. 12.7%, P = 0.001) significantly increases the rate of pCR in the breast and the axilla (TpCR) and the overall response rate (ORR; 93.5% vs. 73.0%, P = 0.003). The occurrence of grade 3-4 anemia and thrombocytopenia is higher in the TEL group (52.5% vs. 10.0% and 34.4% vs. 1.7% respectively). These results demonstrate that the addition of L to the TE regimen as neoadjuvant chemotherapy improves the TpCR and the ORR rates of TNBC but with increased side effects.

引用

页数：8

共 50 条

[21] Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial [J].

Lee, Dae-Won ;

Jung, Kyung Hae ;

Lee, Kyung-Hun ;

Park, Yeon Hee ;

Lee, Keun Seok ;

Sohn, Joohyuk ;

Ahn, Hee Kyung ;

Jeong, Jae Ho ;

Koh, Su-Jin ;

Kim, Jee Hyun ;

Kim, Han Jo ;

Lee, Kyoung Eun ;

Kim, Hee-Jun ;

Park, Kyong Hwa ;

Yang, Yae-Won ;

Lee, Jieun ;

Won, Hye Sung ;

Kim, Tae-Yong ;

Im, Seock-Ah .

EUROPEAN JOURNAL OF CANCER, 2024, 197

[22] An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy [J].

Noguchi, Masanori ;

Matsumoto, Kazumasa ;

Uemura, Hirotsugu ;

Arai, Gaku ;

Eto, Masatoshi ;

Naito, Seiji ;

Ohyama, Chikara ;

Nasu, Yasutomo ;

Tanaka, Masatoshi ;

Moriya, Fukuko ;

Suekane, Shigetaka ;

Matsueda, Satoko ;

Komatsu, Nobukazu ;

Sasada, Tetsuro ;

Yamada, Akira ;

Kakuma, Tatsuyuki ;

Itoh, Kyogo .

CLINICAL CANCER RESEARCH, 2016, 22 (01) :54-60

[23] Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial [J].

Chaft, Jamie E. ;

Oezkan, Filiz ;

Kris, Mark G. ;

Bunn, Paul A. ;

Wistuba, Ignacio I. ;

Kwiatkowski, David J. ;

Owen, Dwight H. ;

Tang, Yan ;

Johnson, Bruce E. ;

Lee, Jay M. ;

Lozanski, Gerard ;

Pietrzak, Maciej ;

Seweryn, Michal ;

Byun, Woo Yul ;

Schulze, Katja ;

Nicholas, Alan ;

Johnson, Ann ;

Grindheim, Jessica ;

Hilz, Stephanie ;

Shames, David S. ;

Rivard, Chris ;

Toloza, Eric ;

Haura, Eric B. ;

McNamee, Ciaran J. ;

Patterson, G. Alexander ;

Waqar, Saiama N. ;

Rusch, Valerie W. ;

Carbone, David P. .

NATURE MEDICINE, 2022, 28 (10) :2155-+

[24] Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial [J].

Lin, Yan ;

Wang, Changjun ;

Huang, Xin ;

Zhou, Xingtong ;

Zhou, Yidong ;

Mao, Feng ;

Guan, Jinghong ;

Song, Yu ;

Zhong, Ying ;

Xu, Ying ;

Sun, Qiang .

BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (03) :659-666

[25] An open-label, single-arm phase II clinical study of docetaxel plus lobaplatin for Chinese patients with pulmonary and hepatic metastasis of nasopharyngeal carcinoma [J].

Zhang, Shuai ;

Chen, Junni ;

Yang, Shiping ;

Lin, Shaomin .

ANTI-CANCER DRUGS, 2016, 27 (07) :685-688

[26] Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905) [J].

Kim, H. R. ;

Jung, K. H. ;

Im, S. -A. ;

Im, Y. -H. ;

Kang, S. Y. ;

Park, K. H. ;

Lee, S. ;

Kim, S. -B. ;

Lee, K. -H. ;

Ahn, J. S. ;

Kim, S. I. ;

Sohn, J. H. .

ANNALS OF ONCOLOGY, 2013, 24 (06) :1485-1490

[27] Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial [J].

Wang, Leiping ;

Cao, Jun ;

Li, Chunlei ;

Wang, Xiaodong ;

Zhao, Yannan ;

Li, Ting ;

Du, Yiqun ;

Tao, Zhonghua ;

Peng, Wenxia ;

Wang, Biyun ;

Zhang, Jian ;

Zhang, Sheng ;

Wang, Zhonghua ;

Hu, Xichun .

INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) :330-339

[28] Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial [J].

Li, Li ;

Zhuang, Qingqing ;

Cao, Zeyi ;

Yin, Rutie ;

Zhu, Yaping ;

Zhu, Lirong ;

Xie, Xing ;

Zhang, Youzhong ;

Li, Li ;

Wu, Qiang ;

Zheng, Jianhua ;

Zhou, Qi ;

Li, Xiaoping ;

Wu, Lingying ;

Feng, Youji ;

Wang, Changyu .

ONCOLOGY LETTERS, 2018, 15 (03) :3646-3652

[29] Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial [J].

Ellis, Paul ;

Barrett-Lee, Peter ;

Johnson, Lindsay ;

Cameron, David ;

Wardley, Andrew ;

O'Reilly, Susan ;

Verrill, Mark ;

Smith, Ian ;

Yarnold, John ;

Coleman, Robert ;

Earl, Helena ;

Canney, Peter ;

Twelves, Chris ;

Poole, Christopher ;

Bloomfield, David ;

Hopwood, Penelope ;

Johnston, Stephen ;

Dowsett, Mitchell ;

Bartlett, John M. S. ;

Ellis, Ian ;

Peckitt, Clare ;

Hall, Emma ;

Bliss, Judith M. .

LANCET, 2009, 373 (9676) :1681-1692

[30] Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial [J].

Yang, Houpu ;

Xu, Ling ;

Guan, Shan ;

Hao, Xiaopeng ;

Ge, Zhicheng ;

Tong, Fuzhong ;

Cao, Yingming ;

Liu, Peng ;

Zhou, Bo ;

Cheng, Lin ;

Liu, Miao ;

Liu, Hongjun ;

Xie, Fei ;

Wang, Siyuan ;

Peng, Yuan ;

Wang, Chaobin ;

Wang, Shu .

BMC CANCER, 2022, 22 (01)

← 1 2 3 4 5 →